Molnupiravir and Combination of Nirmatrelvir and Ritonavir (PaxlovidTM) - Oral Anti-viral Drugs in COVID-19: A Systematic Review
Abstract
The COVID-19 pandemic situation demands the discovery of newer drugs and/ or repurposing of the existing drugs. The anti-viral drugs approved for COVID-19 are remdesivir and favipiravir. Two more directly acting oral anti-viral drugs have been granted Emergency Use Authorization by US-FDA, molnupiravir on December 23, 2021, and nirmatrelvir and ritonavir (PaxlovidTM) on December 22, 2021. Molnupiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, has also been approved in the UK and is under review with other regulatory agencies. PaxlovidTM (a combination of the new anti-viral drugs nirmatrelvir and ritonavir) has been developed and approved by US-FDA and CDSCO, India. Nirmatrelvir acts by inhibiting 3CL (chymotrypsin-like) protease enzyme and it is combined with ritonavir to slow down its breakdown by cytochrome P450 enzymes and to increase the bioavailability. Both molnupiravir and PaxlovidTM have been approved for mild and moderate COVID-19 and in patients who have a higher risk of disease progression to severe disease including hospitalisation and death. This article systematically reviews the clinical trials of molnupiravir and PaxlovidTM that evaluated their efficacy and safety against COVID-19 in both published and unpublished literature.
How to cite this article:
Elango A, Sundaramoorthy K, Subramanian RA, Lella T, Radhakrishnan AK. Molnupiravir and Combination of Nirmatrelvir and Ritonavir (PaxlovidTM) - Oral Anti-viral Drugs in COVID-19: A Systematic Review. J Commun Dis. 2023;55(1):64-73.
DOI: https://doi.org/10.24321/0019.5138.202310
References
US Food & Drug Administration [Internet]. Coronavirus (COVID-19) update: FDA authorizes additional oral
antiviral for treatment of COVID-19 in certain adults;[cited 2022 Dec 4]. Available from: https://www.fda.
gov/news-events/press-announcements/coronaviruscovid-19-update-fda-authorizes-additional-oralantiviral-
treatment-covid-19-certain
US Food & Drug Administration [Internet]. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral
for treatment of COVID-19; [cited 2022 Dec 4]. Available from: https://www.fda.gov/news-events/
press-announcements/coronavirus-covid-19-updatefda-authorizes-first-oral-antiviral-treatment-covid-19
Imran M, Arora MK, Asdaq SM, Khan SA, Alaqel SI, Alshammari MK, Alshehri MM, Alshrari AS, Ali AM,
Al-Shammeri AM, Alhazmi BD, Harshan AA, Alam MT, Abida. Discovery, development, and patent trends
on molnupiravir: a prospective oral treatment for COVID-19. Molecules. 2021;26(19):5795. [PubMed]
[Google Scholar]
Toots M, Yoon JJ, Cox RM, Hart M, Sticher ZM, Makhsou N, Plesker R, Barrena AH, Reddy PG, Mitchell DG, Shean
RC, Bluemling GR, Kolykhalov AA, Greninger AL, Natchus MG, Painter GR, Plemper RK. Characterization of orally
efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med.
;23;11(515):eaax5866. [PubMed] [Google Scholar]
Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH 3rd,
Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR,
Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R,
Denison MR, Baric RS. An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway
epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;29;12(541):eabb5883.
[PubMed] [Google Scholar]
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-
blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6(1):11-8. [PubMed] [Google Scholar]
Gov.uk [Internet]. Summary of product characteristics for Lagevrio; [cited 2022 Dec 4]. Available from: https://
www.gov.uk/government/publications/regulatoryapproval-of-lagevrio-molnupiravir/summary-ofproduct-
characteristics-for-lagevrio
Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv [Preprint]. 2021 Jan 1 [cited 2022 Dec 4]. Available from: https://www.
medrxiv.org/content/10.1101/2021.06.17.21258639v1 [PubMed] [Google Scholar]
Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine
protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol. 2021;49:36-40. [PubMed] [Google Scholar]
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H,
Hammond H, Hammond J, Haupt RE, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy
EK, Lillis JR, Logue J, Luthra SA, Ma C, Mason SW, McGrath ME, Noell S, Obach RS, O’ Brien MN, O’Connor
R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers TF, Rosales R, Rossulek MI, Sathish JG, Shirai N, Steppan
C, Ticehurst M, Updyke LW, Weston S, Zhu Y, White KM, GarcÃa-Sastre A, Wang J, Chatterjee AK, Mesecar
AD, Frieman MB, Anderson AS, Allerton C. Preclinical characterization of an intravenous coronavirus 3CL
protease inhibitor for the potential treatment of COVID19. Nat Commun. 2021;18;12(1):6055. [PubMed]
[Google Scholar]
Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H,
Hammond J, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR,
Luthra SA, Ma C, Noell S, Obach RS, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers T, Rossulek MI,
Sathish JG, Steppan C, Ticehurst M, Updyke LW, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Anderson AS,
Allerton C. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential
treatment of COVID-19. BioRxiv [Preprint]. 2021 Jan 1 [cited 2022 Dec 4]:2020-09. https://www.biorxiv.
org/content/10.1101/2020.09.12.293498v3 [Google Scholar]
Merck [Internet]. Merck and Ridgeback’s investigational oral antiviral molnupiravir reduced the risk of
hospitalization or death by approximately 50 percent compared to placebo for patients with mild or
moderate COVID-19 in positive interim analysis of phase 3 study; [cited 2022 Dec 4]. Available from:
risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-withmild-
or-moderat/
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NC, Morin MJ, Szewczyk LJ, Painter GR.
Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral
agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;1;65(5):e02428-20. [PubMed]
[Google Scholar]
Clinical Trials Registry - India [Internet]; [cited 2022 Dec 4]. Available from: https://ctri.nic.in/Clinicaltrials/
login.php15. Pfizer [Internet]. Pfizer’s Novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPICHR study; [cited 2022 Dec 4]. Available from: https://www.pfizer.com/news/press-release/press-releasedetail/pfizers-novel-covid-19-oral-antiviral-treatmentcandidate
Arunachalam R, Ilamathi KR, Radhakrishnan A, Kumar UP [Internet]. COVID-19: clinical trials and potential
therapeutic agents-a narrative review; 2020 Jul 10 [cited 2022 Dec 4]. Available from: https://papers.ssrn.
com/sol3/papers.cfm?abstract_id=3653031
Copyright (c) 2023 Auhtor's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
